MA26998A1 - Conjugues peg de hgt-nk4 - Google Patents
Conjugues peg de hgt-nk4Info
- Publication number
- MA26998A1 MA26998A1 MA27285A MA27285A MA26998A1 MA 26998 A1 MA26998 A1 MA 26998A1 MA 27285 A MA27285 A MA 27285A MA 27285 A MA27285 A MA 27285A MA 26998 A1 MA26998 A1 MA 26998A1
- Authority
- MA
- Morocco
- Prior art keywords
- hgt
- peg conjugates
- conjugates
- peg
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01104640A EP1234583A1 (fr) | 2001-02-23 | 2001-02-23 | Conjugués du PEG et du HGF-NK4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26998A1 true MA26998A1 (fr) | 2004-12-20 |
Family
ID=8176596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27285A MA26998A1 (fr) | 2001-02-23 | 2003-08-19 | Conjugues peg de hgt-nk4 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20030012775A1 (fr) |
| EP (2) | EP1234583A1 (fr) |
| JP (2) | JP2004521139A (fr) |
| KR (2) | KR20090020713A (fr) |
| CN (1) | CN100339393C (fr) |
| AR (1) | AR032574A1 (fr) |
| AU (1) | AU2002233354B2 (fr) |
| BG (1) | BG108125A (fr) |
| BR (1) | BR0207510A (fr) |
| CA (1) | CA2438308A1 (fr) |
| CZ (1) | CZ20032511A3 (fr) |
| EC (1) | ECSP034741A (fr) |
| GT (1) | GT200200038A (fr) |
| HR (1) | HRP20030659A2 (fr) |
| HU (1) | HUP0400979A2 (fr) |
| IL (1) | IL157426A0 (fr) |
| MA (1) | MA26998A1 (fr) |
| MX (1) | MXPA03007130A (fr) |
| NO (1) | NO20033737L (fr) |
| PA (1) | PA8540501A1 (fr) |
| PE (1) | PE20020992A1 (fr) |
| PL (1) | PL367402A1 (fr) |
| RU (1) | RU2293574C2 (fr) |
| SK (1) | SK11652003A3 (fr) |
| WO (1) | WO2002074344A2 (fr) |
| YU (1) | YU65103A (fr) |
| ZA (1) | ZA200306080B (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004019991A2 (fr) * | 2002-08-30 | 2004-03-11 | F. Hoffmann-La Roche Ag | Antagoniste nk4 du facteur de croissance de l'hepatocyte/du facteur de dispersion pour le traitement de gliome |
| WO2004085471A2 (fr) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Derives de glp-2 |
| ES2297673T3 (es) * | 2004-03-03 | 2008-05-01 | F. Hoffmann-La Roche Ag | Metodo para la purificacion de un fragmento n-terminal del factor de crecimiento de hepatocitos. |
| CA2558742A1 (fr) * | 2004-03-03 | 2005-10-13 | F. Hoffmann-La Roche Ag | Methode d'expression par recombinaison d'un fragment n-terminal du facteur de croissance de l'hepatocyte |
| US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
| ES2556711T3 (es) * | 2008-04-09 | 2016-01-19 | Viromed Co., Ltd. | Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico |
| CN102399293B (zh) * | 2008-06-03 | 2013-12-04 | 中国科学院遗传与发育生物学研究所 | 一种与纤维蛋白特异结合的重组蛋白及其应用 |
| US10532020B2 (en) | 2012-08-22 | 2020-01-14 | Revlon Consumer Products Corporation | Nail coatings having enhanced adhesion |
| US9943568B2 (en) | 2013-04-18 | 2018-04-17 | Armo Biosciences, Inc. | Methods of using pegylated interleukin-10 for treating cancer |
| ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
| CN105658232A (zh) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
| WO2015070060A1 (fr) | 2013-11-11 | 2015-05-14 | Armo Biosciences, Inc. | Méthodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles |
| US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| MX2017004838A (es) | 2014-10-14 | 2017-10-16 | Armo Biosciences Inc | Composiciones de interleucina-15 y usos de estas. |
| AU2015336101A1 (en) | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| EP3302547A1 (fr) | 2015-05-28 | 2018-04-11 | Armo Biosciences, Inc. | Interleukine 10 pégylée utilisée pour le traitement du cancer |
| EP3341012A4 (fr) | 2015-08-25 | 2019-03-20 | Armo Biosciences, Inc. | Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles |
| CA3125320A1 (fr) * | 2019-01-28 | 2020-08-06 | Toray Industries, Inc. | Forme modifiee par du polyethylene glycol d'un facteur de croissance des hepatocytes ou d'un fragment actif de celui-ci |
| WO2020158691A1 (fr) * | 2019-01-28 | 2020-08-06 | 東レ株式会社 | Corps modifié de polyéthylène glycol pour facteur de croissance des hépatocytes ou fragment actif associé |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2118012A1 (fr) | 1992-05-18 | 1993-11-25 | Paul J. Godowski | Variantes du facteur de croissance des hepatocytes |
| US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
| GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
| HU218893B (hu) * | 1994-03-31 | 2000-12-28 | Amgen Inc. | A megakariocita szaporodás és differenciálódás stimulálására szolgáló módszerek és vízoldható készítmények |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| WO1996028475A1 (fr) * | 1995-03-10 | 1996-09-19 | Nakamura, Toshikazu | Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol |
| DE741187T1 (de) * | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
| US6025324A (en) * | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
| ATE342729T1 (de) * | 1997-01-15 | 2006-11-15 | Phoenix Pharmacologics Inc | Modifizierter tumor-nekrosefaktor |
| US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| EP0922446A1 (fr) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site |
| DK1421956T3 (da) * | 1998-04-28 | 2007-10-01 | Applied Research Systems | Polyol-IFN-beta-konjugater |
| US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| JP4656814B2 (ja) * | 2000-12-20 | 2011-03-23 | エフ．ホフマン−ラ ロシュ アーゲー | エリスロポエチンコンジュゲート |
-
2001
- 2001-02-23 EP EP01104640A patent/EP1234583A1/fr not_active Withdrawn
-
2002
- 2002-02-20 PE PE2002000144A patent/PE20020992A1/es not_active Application Discontinuation
- 2002-02-20 PA PA20028540501A patent/PA8540501A1/es unknown
- 2002-02-21 RU RU2003127395/15A patent/RU2293574C2/ru not_active IP Right Cessation
- 2002-02-21 SK SK1165-2003A patent/SK11652003A3/sk unknown
- 2002-02-21 HU HU0400979A patent/HUP0400979A2/hu unknown
- 2002-02-21 JP JP2002573051A patent/JP2004521139A/ja not_active Withdrawn
- 2002-02-21 AR ARP020100593A patent/AR032574A1/es not_active Application Discontinuation
- 2002-02-21 PL PL02367402A patent/PL367402A1/xx not_active Application Discontinuation
- 2002-02-21 CA CA002438308A patent/CA2438308A1/fr not_active Abandoned
- 2002-02-21 IL IL15742602A patent/IL157426A0/xx unknown
- 2002-02-21 BR BR0207510-5A patent/BR0207510A/pt not_active IP Right Cessation
- 2002-02-21 CZ CZ20032511A patent/CZ20032511A3/cs unknown
- 2002-02-21 WO PCT/EP2002/001837 patent/WO2002074344A2/fr not_active Application Discontinuation
- 2002-02-21 EP EP02700263A patent/EP1389132A2/fr not_active Withdrawn
- 2002-02-21 KR KR1020097002234A patent/KR20090020713A/ko not_active Application Discontinuation
- 2002-02-21 KR KR10-2003-7010748A patent/KR20030072629A/ko active Search and Examination
- 2002-02-21 US US10/081,309 patent/US20030012775A1/en not_active Abandoned
- 2002-02-21 MX MXPA03007130A patent/MXPA03007130A/es not_active Application Discontinuation
- 2002-02-21 AU AU2002233354A patent/AU2002233354B2/en not_active Ceased
- 2002-02-21 YU YU65103A patent/YU65103A/sh unknown
- 2002-02-21 CN CNB028052951A patent/CN100339393C/zh not_active Expired - Fee Related
- 2002-02-22 GT GT200200038A patent/GT200200038A/es unknown
-
2003
- 2003-08-06 ZA ZA200306080A patent/ZA200306080B/en unknown
- 2003-08-19 HR HR20030659A patent/HRP20030659A2/hr not_active Application Discontinuation
- 2003-08-19 MA MA27285A patent/MA26998A1/fr unknown
- 2003-08-21 EC EC2003004741A patent/ECSP034741A/es unknown
- 2003-08-22 BG BG108125A patent/BG108125A/bg unknown
- 2003-08-22 NO NO20033737A patent/NO20033737L/no not_active Application Discontinuation
-
2007
- 2007-10-10 US US11/869,797 patent/US7846896B2/en not_active Expired - Lifetime
-
2010
- 2010-04-22 JP JP2010099120A patent/JP2010174034A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR17C1054I2 (fr) | Conjugues de type vecteur-derive de calicheamicine | |
| ATE524462T1 (de) | C5-modifizierte indazolylpyrrolotriazine | |
| DE50103741D1 (de) | Welle-Nabe-Verbindung | |
| MA26998A1 (fr) | Conjugues peg de hgt-nk4 | |
| NO20033059L (no) | Silrörsdeksel | |
| ATE335486T1 (de) | Hydrazono-malonitrile | |
| DE1319930T1 (de) | Coriolismassendurchflussmesser | |
| PT1268453E (pt) | Metabolitos de agonista/antagonista de estrogenio | |
| DE50208386D1 (de) | Durchbiegungseinstellwalze | |
| DE50203412D1 (de) | Schwenkkolbenverdränger | |
| EE200300480A (et) | Pregabaliini-laktoosi konjugaadid | |
| ATE355059T1 (de) | Isoxazolopyridinone | |
| DE50201862D1 (de) | Messwandler | |
| DE50207767D1 (de) | Durchbiegungseinstellwalze | |
| PT1317179E (pt) | Formulacoes de mesotriona | |
| DE50212401D1 (de) | Durchbiegungseinstellwalze | |
| DE50203093D1 (de) | Losradlager | |
| DE60143209D1 (de) | Zweiport-demodulationseinrichtung | |
| ATE319694T1 (de) | Phenylalkyne | |
| ATA18372001A (de) | Gelenksbolzenbaueinheit | |
| NO20035742L (no) | Kjemisk modifisert progenipoietin konjugater | |
| DE50202088D1 (de) | Garmodulsystem | |
| DE60229395D1 (de) | Altung | |
| DE10295006D2 (de) | Bauwerksabdichtung | |
| DE50108381D1 (de) | Synchronisierschaltungsanordnung |